Document is current
Any future updates will be listed below
-
Authors
Ludvigsson, Jonas F. https://orcid.org/0000-0003-1024-5602
Bergman, David https://orcid.org/0000-0003-4808-1762
Lundgren, Catharina Ihre https://orcid.org/0000-0003-2114-5949
Sundquist, Kristina https://orcid.org/0000-0001-8031-279X
Geijerstam, Jean-Luc af
Glenngård, Anna H. https://orcid.org/0000-0001-7500-4610
Lindh, Marie
Sundström, Johan https://orcid.org/0000-0003-2247-8454
Kaarme, Johan
Yao, Jialu https://orcid.org/0009-0004-2238-6810
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 23 March 2025
First Online: 19 May 2025
Declarations
:
: Dr Sundström reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) and services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, and WeMind..
